MYRIAD GENETICS INC 8-K

What Happened

• On January 12, 2026, Myriad Genetics, Inc. (MYGN) issued a press release (furnished as Exhibit 99.1) reporting preliminary revenue results for the quarter and full year ended December 31, 2025 and introducing full‑year 2026 financial guidance. The release also provided preliminary volume data for 2025.
• The company expects total test volumes in 2025 of approximately 1.5 million, a ~1% year‑over‑year increase, with hereditary cancer tests up ~7%, mental health tests up ~6%, and prenatal health tests down ~4%. The filing notes these results are preliminary, subject to normal close and audit procedures, and include forward‑looking statements.

Key Details

• Date filed: January 12, 2026 (Current Report on Form 8‑K).
• Total tests 2025: ~1.5 million (≈ +1% YoY).
• Volume mix: hereditary cancer +7% YoY; mental health +6% YoY; prenatal health −4% YoY.
• Preliminary financial results and 2026 guidance are subject to final accounting and external audit; see Exhibit 99.1 for full press release and cautionary language.

Why It Matters

• Test volume trends give a direct view into core demand drivers: growth in hereditary cancer and mental health testing could support revenue gains, while prenatal testing weakness may weigh on topline mix.
• Because the revenue figures are preliminary and subject to audit, investors should treat the numbers as provisional and watch for the company’s final results and any updates to 2026 guidance.
• The introduction of full‑year 2026 guidance means management is setting expectations for next-year performance; investors should review the detailed guidance in the press release and the company’s subsequent earnings release or 10‑K for finalized results.